FY2024 EPS Estimates for TSE:GLX Decreased by Analyst

Bradmer Pharmaceuticals Inc. (TSE:GLXFree Report) – Equities researchers at Atb Cap Markets reduced their FY2024 EPS estimates for Bradmer Pharmaceuticals in a research report issued on Sunday, January 26th. Atb Cap Markets analyst M. Toner now forecasts that the company will post earnings of $3.01 per share for the year, down from their prior forecast of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.

Bradmer Pharmaceuticals (TSE:GLXGet Free Report) last posted its earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share for the quarter, beating the consensus estimate of C($0.52) by C$0.34.

Separately, HC Wainwright raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 10th.

View Our Latest Report on GLX

Bradmer Pharmaceuticals Price Performance

Read More

Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.